Perinatal Outcomes in Women with COVID-19: A Global Review
The COVID-19 pandemic changed pregnancy care across every region, from highly resourced maternity units to hospitals operating with limited staffing and equipment. It also exposed how strongly perinatal outcomes depend on timing, access to care, vaccination, viral variant, maternal health, and the capacity of health systems to respond quickly.
Evidence gathered since 2020 shows that SARS-CoV-2 infection during pregnancy can increase the risk of severe maternal disease and several adverse birth outcomes. The level of risk has varied considerably, however. Early studies often reflected the effects of the original virus, limited testing, delayed treatment, and unvaccinated populations, while later research has included vaccination and newer variants.
A global review therefore needs to look beyond a single percentage or headline finding. It must distinguish infection from symptomatic disease, identify the outcomes most consistently associated with COVID-19, and account for the social and clinical conditions that shape pregnancy and newborn survival.
How Pregnancy Changes COVID-19 Risk
Pregnancy produces normal changes in the cardiovascular, respiratory, and immune systems. Increased oxygen consumption, reduced respiratory reserve, and altered immune regulation can make respiratory viral infections more difficult to tolerate. These changes do not mean that every pregnant person will develop severe COVID-19, but they help explain why hospitalization, intensive care, and respiratory support have been more common in infected pregnant populations than in nonpregnant adults of similar age.
Risk is higher when infection occurs alongside obesity, diabetes, chronic hypertension, cardiovascular disease, or lung disease. Older maternal age and limited access to prenatal care can add further risk. Severe maternal illness may involve pneumonia, hypoxemia, thromboembolic complications, kidney injury, or the need for mechanical ventilation. Pregnancy itself is also a hypercoagulable state, so clinical teams must assess clotting risk carefully while balancing bleeding concerns around delivery.
The timing of infection matters. An infection late in pregnancy may be more likely to coincide with delivery, hospitalization, or medically indicated preterm birth. Infection earlier in gestation can disrupt routine antenatal appointments and increase anxiety, but evidence for a consistent pattern of congenital malformations remains limited. The virus is not generally classified as a major teratogen in the way that certain medications or infections are.
What Global Studies Show About Mothers
Across observational studies and systematic reviews, severe COVID-19 during pregnancy has been associated with higher rates of intensive care admission, oxygen therapy, and maternal death than mild or asymptomatic infection. Absolute risks remain low in many settings, but the increase is clinically meaningful because pregnant patients may deteriorate rapidly and require coordinated obstetric, respiratory, and critical care.
The risk profile shifted as clinical management improved. Early in the pandemic, fear of transmission sometimes led to delayed presentation, separation policies, and uncertainty about delivery timing. Later protocols emphasized early assessment of oxygenation, appropriate antiviral or immunomodulatory treatment when indicated, thrombosis prevention, and multidisciplinary planning. Vaccination substantially reduced severe disease, hospitalization, and death, although protection against infection itself changed with circulating variants.
The pandemic also affected maternal outcomes indirectly. Women missed appointments because of transport restrictions, fear of infection, clinic closures, or caregiving responsibilities. In some countries, shortages of midwives, blood products, personal protective equipment, and emergency transport increased the danger of otherwise manageable complications. These indirect effects are especially important when comparing wealthy and low-resource settings.
For background on how the pandemic disrupted international scientific exchange and perinatal collaboration, the conference impact report provides useful context. The cancellation of major meetings also slowed the informal sharing of emerging clinical experience at a time when guidance was changing quickly.
Birth Outcomes And Newborn Health
Preterm birth is the outcome most consistently linked with maternal COVID-19, particularly when infection is moderate or severe. Some preterm deliveries are spontaneous, but many are medically indicated because of maternal respiratory failure, fetal compromise, preeclampsia-like illness, or the need to stabilize the mother. This distinction matters: the infection may influence the decision to deliver without directly initiating labor.
Studies have also reported increased rates of stillbirth and fetal growth concerns in selected populations, especially during waves involving severe disease and strained health services. The association is not uniform across all countries or periods. Underdiagnosis, differences in stillbirth definitions, incomplete vaccination, and interruptions to antenatal monitoring can affect results. Placental inflammation, vascular injury, and reduced oxygen exchange are possible biological pathways, but the contribution of each mechanism varies.
Newborns of infected mothers may be more likely to require neonatal intensive care, largely because of prematurity or maternal complications. Most infants do well when they receive timely neonatal support. SARS-CoV-2 transmission from mother to baby around birth is possible but relatively uncommon, and a positive neonatal test does not always establish when transmission occurred.
Breast milk has not generally been considered a major route of infectious transmission. Current practice in many settings supports breastfeeding with hand hygiene, masking when appropriate, and careful infection-control measures. The benefits of human milk, skin-to-skin contact, and parental involvement should be preserved whenever the mother and infant are clinically stable.
| Outcome or concern | Pattern reported in global evidence | Main factors that change the risk |
|---|---|---|
| Severe maternal illness | Higher than in comparable nonpregnant adults, especially with symptomatic infection | Variant, vaccination, comorbidities, access to oxygen and critical care |
| Preterm birth | Frequently increased, with many cases medically indicated | Maternal hypoxemia, fetal status, hypertensive disease, hospital policy |
| Stillbirth | Increased in some populations and pandemic waves | Infection severity, placental effects, delayed care, antenatal service disruption |
| Cesarean delivery | Often higher in early reports, though practice varies widely | Maternal condition, fetal monitoring, local protocols, clinician caution |
| Neonatal intensive care | More common, primarily because of prematurity or maternal illness | Gestational age, neonatal resources, referral capacity |
| Neonatal infection | Possible but uncommon | Timing of infection, testing practices, birth precautions, variant |
Vaccination And Treatment During Pregnancy
Pregnancy was initially excluded or underrepresented in many vaccine trials, creating uncertainty just when pregnant people faced substantial exposure risk. Subsequent safety surveillance and large observational studies have generally supported COVID-19 vaccination during pregnancy. Vaccination has not been associated with a broad increase in miscarriage, congenital anomalies, or infertility, and it can provide antibodies that cross the placenta and may help protect the newborn during early life.
The benefits are clearest for preventing severe maternal disease. Vaccination status should therefore be interpreted alongside the current variant, local transmission, previous infection, available products, and individual medical history. Clear counseling is essential because misinformation and inconsistent public messaging have reduced uptake in some communities.
Treatment decisions should be made promptly rather than waiting for severe deterioration. Depending on local guidance and patient factors, care may include antiviral therapy, corticosteroids for patients requiring oxygen, antipyretics, respiratory support, and anticoagulation assessment. Medication selection requires attention to gestational age, drug interactions, renal and hepatic function, and the evidence available for pregnancy.
A pregnant patient with COVID-19 needs the same careful clinical assessment as any other high-risk respiratory patient, with additional attention to fetal well-being and delivery planning. Oxygen targets, escalation thresholds, and consultation pathways should be agreed in advance. A positive test alone is not an indication for cesarean birth or early delivery; the decision should reflect maternal and fetal status.
Why Outcomes Differ Across Regions
Global comparisons are complicated by differences in surveillance. Countries with widespread testing identify more mild infections, while areas with limited laboratory capacity may record mainly hospitalized cases. This can make disease appear more severe in one population simply because mild cases were missed elsewhere. Differences in admission thresholds, stillbirth registration, gestational age definitions, and follow-up duration create additional uncertainty.
Health-system capacity is a central determinant. An infected pregnant woman treated quickly in a facility with oxygen, fetal monitoring, intensive care, and emergency surgery may have a very different outcome from a woman who must travel several hours during a lockdown. The same biological infection can produce different consequences when referral networks, transport, or blood supplies are unreliable.
Social conditions also shape exposure and recovery. Frontline work, crowded housing, limited sick leave, language barriers, digital exclusion, and unequal access to vaccination can raise risk. Racial and ethnic disparities reported in several countries often reflect cumulative structural disadvantage, comorbidities, occupational exposure, and differences in access to timely care rather than an inherent biological vulnerability.
Research should therefore report more than aggregate outcomes. Studies need to include vaccination status, variant period, severity at presentation, treatment received, gestational age, maternal comorbidities, and indicators of healthcare access. Without these details, global averages can conceal both preventable risk and successful clinical practice.
Priorities For Safer Perinatal Care
Maternity services can prepare for future respiratory outbreaks by combining infection control with continuity of essential care. Remote appointments may help with selected follow-ups, but they cannot replace blood pressure checks, fetal growth assessment, screening, vaccination counseling, or emergency evaluation when those services are clinically necessary. Clear triage systems should distinguish routine questions from warning signs such as breathlessness, reduced fetal movement, persistent fever, chest pain, or confusion.
Hospitals also need protocols that protect staff without isolating families unnecessarily. Separate pathways, appropriate ventilation, personal protective equipment, and rapid testing can reduce exposure while preserving partner participation and parental contact. Neonatal units should plan for staffing shortages, transport delays, and the safe use of expressed breast milk when direct breastfeeding is temporarily difficult.
Useful priorities for clinicians, health leaders, and researchers include:
- Offer evidence-based COVID-19 vaccination counseling before and during pregnancy, with access to boosters when recommended.
- Establish rapid assessment pathways for pregnant patients with respiratory symptoms or reduced oxygen saturation.
- Record infection severity, treatment, vaccination, variant period, gestational age, and delivery indication in outcome studies.
- Protect antenatal, ultrasound, referral, and emergency obstetric services during public-health restrictions.
- Support breastfeeding, skin-to-skin care, and family involvement with practical infection-control measures.
The FAOPS 2020 archive reflects the wider perinatal research community that sought to connect specialists across Asia and Oceania before the Tokyo congress was canceled. That collaborative spirit remains important: pregnancy-related COVID-19 evidence evolves across countries, and no single health system can answer every question alone.
Turning Evidence Into Clinical Action
The strongest overall message is that COVID-19 in pregnancy should be treated as a preventable and manageable clinical risk, not as an automatic reason for intervention. Vaccination, early recognition, timely treatment, appropriate escalation, and continuity of maternity care can reduce severe outcomes. At the same time, clinicians should avoid minimizing mild illness or assuming that a reassuring first assessment eliminates the need for follow-up.
For families, reliable advice should explain both the risks of infection and the benefits of available preventive measures without exaggeration. For policymakers, the evidence supports investment in maternal vaccination, laboratory testing, oxygen systems, referral transport, neonatal capacity, and high-quality surveillance. For researchers, the next stage is to produce more representative data from low- and middle-income settings and to follow infants beyond the immediate newborn period.
Use the evidence to strengthen local pregnancy-care pathways, update counseling materials, and build cooperation between obstetric, neonatal, infectious-disease, and public-health teams. Consistent action across those services can turn lessons from the pandemic into safer outcomes for mothers and babies during the next respiratory health emergency.
